Filing Flows › Skinvisible (SKVI) › Q1 2026 › vs Q4 2025
Skinvisible (SKVI) Q1 2026 vs Q4 2025 (quarter over quarter)
Skinvisible's revenue rose $0 (0%) from $5K in Q4 2025 to $5K in Q1 2026.
Skinvisible, Q1 2026: revenue $5K (0% year over year), net loss $267K, operating cash flow −$1K. The chart draws each line against Q4 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q4 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $5K | $5K | $0 | 0% |
| Net loss | $267K | $258K | $9K | +3% |
| Costs & expenses | $272K | $263K | $9K | +3% |
| Operating costs | $131K | $119K | $12K | +10% |
| Interest & other, net | $141K | $144K | −$3K | -2% |
| Cost of revenue | $0 | $0 | $0 | — |
| SG&A | $126K | $114K | $12K | +10% |
| Other operating costs | $5K | $5K | −$111 | -2% |
| Operating cash sources | $267K | $258K | $9K | +3% |
| Depreciation & amortization | $5K | $5K | −$111 | -2% |
| Working capital & other | $261K | $255K | $6K | +2% |
| Cash used in operations | $1K | −$2K | $3K | — |
| Net loss absorbed | $267K | $258K | $9K | +3% |
Questions
How much did Skinvisible's revenue grow quarter over quarter in Q1 2026?
Skinvisible's revenue rose $0 (0%) from $5K in Q4 2025 to $5K in Q1 2026.